ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

ClinicalTrials.gov ID: NCT06962280

Public ClinicalTrials.gov record NCT06962280. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Tirzepatide Once Weekly Compared to Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Study identification

NCT ID
NCT06962280
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
465 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Tirzepatide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 11, 2025
Primary completion
Oct 31, 2026
Completion
Jun 30, 2027
Last update posted
Feb 16, 2026

2025 – 2027

United States locations

U.S. sites
18
U.S. states
9
U.S. cities
18
Facility City State ZIP Site status
Kaiser Permanente Bonita Medical Offices Bonita California 91902
AMCR Institute Escondido California 92025
Mary & Dick Allen Diabetes Center Newport Beach California 92663
University Clinical Investigators, Inc. Tustin California 92780
University of Colorado Anschutz Medical Campus Aurora Colorado 80045
Metabolic Research Institute, Inc. West Palm Beach Florida 33401
Iowa Diabetes and Endocrinology Research Center West Des Moines Iowa 50266
HealthPartners Institute dba International Diabetes Center Minneapolis Minnesota 55416
Clinical Research Professionals Chesterfield Missouri 63005
Clinvest Headlands Llc Springfield Missouri 65807
Las Vegas Endocrinology Henderson Nevada 89074
University of North Carolina Medical Center Chapel Hill North Carolina 27514
Velocity Clinical Research, Dallas Dallas Texas 75230
Juno Research Houston Texas 77040
Southern Endocrinology Associates Mesquite Texas 75149
Texas Diabetes & Endocrinology, P.A. Round Rock Texas 78681
San Antonio Clinical Trials San Antonio Texas 78240
Texas Valley Clinical Research Weslaco Texas 78596

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06962280, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06962280 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →